Hyperbilirubinemia After Cardiac Surgery
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01617902 |
Recruitment Status
: Unknown
Verified June 2012 by Joon Bum Kim, Asan Medical Center.
Recruitment status was: Recruiting
First Posted
: June 13, 2012
Last Update Posted
: June 18, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Cardiovascular Diseases |
Study Type : | Observational |
Estimated Enrollment : | 1000 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Hyperbilirubinemia After Major Cardiac or Thoracic Aorta Surgery: Predictors and Clinical Significance |
Study Start Date : | June 2012 |
Estimated Primary Completion Date : | June 2013 |
Estimated Study Completion Date : | August 2013 |

- All cause-death [ Time Frame: Within 30 days after surgery or during postoperative hospitalization ]
- gastrointestinal or hepatobiliary complications requiring intervention [ Time Frame: Within 30 days after surgery or during postoperative hospitalization ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
Patients aged over 18 years who are scheduled to undergo elective major cardiac or thoracic aorta surgery. Major cardiac surgery includes coronary artery bypass grafting, pericardiectomy and corrections of cardiac diseases using cardiopulmonary bypassing (valve surgery, tumor excision, arrhythmia surgery, heart transplantation, ventricular reconstruction, pulmonary thromboembolectomy, and atrial or ventricular septal defects closure).
Exclusion Criteria:
- univentricular or one-and-half ventricle repairs
- presence of known liver cirrhosis or hepatic cancer
- history of liver transplantation
- Genetic diseases that affects bilirubin metabolism (i.e. Gilbert syndrome)
- preoperative bilirubin level of 3mg/dL or more.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01617902
Contact: Joon Bum Kim, MD | 82-2-3010-5416 | jbkim1975@amc.seoul.kr |
Korea, Republic of | |
Asan Medical Center | Recruiting |
Seoul, Korea, Republic of, 138-736 | |
Contact: Joon Bum Kim, MD 82-2-3010-5416 jbkim1975@amc.seoul.kr |
Principal Investigator: | Joon Bum Kim, MD | Asan Medical Center |
Responsible Party: | Joon Bum Kim, Assistant Professor, Asan Medical Center |
ClinicalTrials.gov Identifier: | NCT01617902 History of Changes |
Other Study ID Numbers: |
HBCS_01 |
First Posted: | June 13, 2012 Key Record Dates |
Last Update Posted: | June 18, 2012 |
Last Verified: | June 2012 |
Keywords provided by Joon Bum Kim, Asan Medical Center:
Hyperbilirubinemia cardiac surgery aorta prognosis |
Additional relevant MeSH terms:
Cardiovascular Diseases Hyperbilirubinemia Pathologic Processes |